KP Biomedical Engineering - Issue #9

-NSF Celebrates 80 Years of Improving Human and Planet Health BANGKOK--(BUSINESS WIRE)

--NSF, a leading global public health and safety organization, recently celebrated its 80th anniversary at its headquarters, offices and laboratories around the world. Founded in 1944 as the National Sanitation Foundation, NSF has evolved into a global services organization at the forefront of standards development, product certification, and testing, serving industries, governments, and consumers in 110 countries.

-CareDx Reports Preliminary Financial Results for Third Quarter 2024BRISBANE, Calif.--(BUSINESS WIRE)

--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company? — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers reported preliminary financial results for the third quarter ended September 30, 2024.

-Tenovi and Nonin Medical Partner to Advance Health Equity via Remote Patient Monitoring for Chronic Care Patients PORTSMOUTH, N.H.--(BUSINESS WIRE)

--Tenovi, the innovator in cellular-connected remote patient monitoring (RPM) solutions, announced a strategic commercial partnership with Nonin Medical, Inc., inventors of the world’s first fingertip pulse oximeter to advance health equity. Low-cost oximeters frequently provide inaccurate readings for patients with darker skin pigmentation, resulting in potential misdiagnosis and inequitable healthcare outcomes.

-One Month Countdown to ventureLAB's 4th Annual HardTech Summit MARKHAM, Ontario--(BUSINESS WIRE)

--ventureLAB in partnership with Regional Municipality of York, is excited to announce the return of Canada’s premier hardtech innovation event, the 4th Annual HardTech Summit, taking place on November 6-7, 2024, at the Toronto Marriott Markham. As Canada’s leading summit focused on Hardware, Semiconductor, MedTech, AI, and Automobility.

-For Patients at Risk, a Simple Blood Test Can Help Doctors Predict Likelihood of Future Heart Attack, Other Cardiac Events, and Death TARRYTOWN, N.Y.--(BUSINESS WIRE)

--A new prognosis claim for the Siemens Healthineers Atellica IM High-Sensitivity Troponin I (TnIH) test1 immediately advances care for at-risk cardiac patients in the U.S. The easy blood test helps healthcare providers identify patients at risk of death and major cardiac events that could occur up to one year after presenting to the emergency department with signs and symptoms of acute coronary syndrome.

-NAMSA and TERUMO Announce Strategic Outsourcing PartnershipTOLEDO, Ohio & TOKYO--(BUSINESS WIRE)

--NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering end-to-end market access services, and TERUMO, a global leader in medical technology, announced that they have entered into a strategic outsourcing partnership aimed at accelerating the regulatory approval and commercialization of Terumo’s product portfolio.

-NOWDiagnostics and Labcorp Collaborate to Expand Access to the Only FDA-Marketing Authorized Over-the-Counter Syphilis Test in the U.S. SPRINGDALE, Ark.--(BUSINESS WIRE)

--NOWDiagnostics, Inc. (NOWDx), a developer of over-the-counter (OTC) and point-of-care (POC) diagnostic tests, announced that Labcorp, a global leader of innovative and comprehensive laboratory services, will be the exclusive U.S. distributor of its First To Know? Syphilis Test in professional and healthcare settings.

-AdaptHealth Corp. Announces Third Quarter 2024 Earnings Release Date and Conference Call PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)

--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, will release its third quarter 2024 financial results before the opening of the financial markets on Tuesday, November 5, 2024.

-Hyperice Unveils Normatec Elite in Canada: The Next Innovation of the Iconic Normatec Line IRVINE, Calif.--(BUSINESS WIRE)

--Hyperice, a global high-performance wellness brand, announced the launch of Normatec Elite, the most advanced and fully integrated dynamic air compression therapy device to date, in Canada. Normatec Elite represents a transformative leap forward in recovery technology, offering athletes and wellness enthusiasts alike a comprehensive and intuitive recovery experience through a fully wireless approach.

-Operationalizing FDA LDT Compliance: Expert Panel Reveals Essential Strategies and Actions for Meeting the 1st Reporting Milestone AUSTIN, Texas--(BUSINESS WIRE)

--Many clinical laboratories are now under the gun to achieve Phase One compliance with the Food and Drug Administration’s (FDA) LDT rule before the May 2025 deadline. Labs performing LDTs must take immediate action to protect their most important LDTs that improve patient care while generating substantial reimbursement. This is a high stakes situation for labs offering LDTs because they have only five months to secure their most valuable LDTs.

-Life Spine Announces Continued Success and Industry Adoption of ProLift? Micro Endoscopic Expandable Spacer System HUNTLEY, Ill.--(BUSINESS WIRE)

--Life Spine, Inc., a leading medical device company specializing in the design, development, manufacturing, and marketing of products for the surgical treatment of spinal disorders, announced the ongoing adoption of its ProLift Micro Endoscopic Expandable Spacer System. This system utilizes the same Micro Invasive? tube for access, disc preparation, and interbody delivery, further advancing the company's approach to Micro Invasive fusions.

-A New Theranostics Center of Excellence in Europe: GE HealthCare and University Medicine Essen Collaborate to Advance Theranostics and Personalized Medicine CHICAGO--(BUSINESS WIRE)

--With the aim of increasing access to precision care, GE HealthCare is proud to collaborate with University Medicine Essen (UME) in the establishment of a new Theranostics Center of Excellence. The Center will be outfitted with the latest technologies and solutions to support the clinical practice and advanced research of more personalized approaches to cancer care in Germany and around the world.

-Paragon 28 Launches the Phantom? Fibula Nail System for Less Invasive Fracture Repair ENGLEWOOD, Colo.--(BUSINESS WIRE)

--Paragon 28, Inc. (NYSE: FNA) is pleased to announce the launch of the Phantom? Fibula Nail System, designed to give surgeons a less invasive option to treat the fibula when patients sustain an ankle fracture. Use of a fibula nail for the treatment of ankle fractures has been shown to have significantly fewer soft tissue complications, implant removals, and fracture nonunion when compared to plate and screw fixation, a common alternative approach.

-Innovative Lab Services LLC Acquires MLS Technologies, Inc. COLUMBUS, Ohio--(BUSINESS WIRE)

--Innovative Lab Services LLC (“ILS”), a premier provider of analytical instrumentation solutions is thrilled to announce its acquisition of MLS Technologies, Inc. (“MLS”), a leading analytical instrument services and support company. This strategic combination will significantly extend the core capabilities, technical expertise and geographic reach of both companies, positioning the platform to better serve the broader life sciences market nationwide.

-Minze Health Raises US$ 5.3 Million in Funding to Develop Prescription Digital Therapeutics and Drive Commercialization in the US Market ANTWERP, Belgium--(BUSINESS WIRE)

--Minze Health, a pioneer in digital health solutions for urology, has successfully secured USD 5.3 million in a funding round led by its existing investors White Fund, Capricorn Digital Growth Fund, and the Flemish investment company PMV. The funding round also saw the participation of a new investor, imec.istart future fund, marking a significant step forward for the company’s growth and innovation.

-Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results QUEENSBURY, N.Y.--(BUSINESS WIRE)

--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced preliminary revenue results for the third quarter of 2024, achieving $11.2 million, which included the recording of $10.0 million in U.S. revenue from the commercialization of HEPZATO KIT.

-Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Continues Its Introduction of LACRIFILL? Canalicular Gel, a Novel Therapy for Dry Eye, During American Academy of Ophthalmology (AAO) 2024 BERWYN, Pa.--(BUSINESS WIRE)

--Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., launched LACRIFILL Canalicular Gel, a novel therapy for dry eye in the U.S. in April and will continue its introduction to leading ophthalmologists during AAO 2024. LACRIFILL Canalicular Gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system.

-Tasso, Inc.’s Survey Unveils One in Three Patients Delay Diagnostic Blood Tests — Anxiety, Pain and Inconvenience of Traditional Phlebotomy Lead to Patients Missing Routine Care SEATTLE--(BUSINESS WIRE)

--Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, surveyed more than 600 adults (age 18-65+) within the United States to assess their experiences and preferences regarding blood testing, as well as their perspectives about the future of patient care.

-Human Factors and Usability Engineering Services Market Industry Trends and Global Forecasts to 2035 - ResearchAndMarkets.com DUBLIN--(BUSINESS WIRE)

--The "Human Factors and Usability Engineering Services Market Industry Trends and Global Forecasts to 2035: Distribution by Steps Involved, Type of Research Method, Class of Medical Device Tested, Geographical Region and Leading Players" report has been added to ResearchAndMarkets.com's offering. The global human factors and usability engineering services market is valued at USD 0.94 billion in 2024, growing at a CAGR of 6.9% during the forecast period till 2035.

-Paragon 28 To Report Third Quarter 2024 Financial Results on November 12, 2024 ENGLEWOOD, Colo.--(BUSINESS WIRE)

--Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the third quarter 2024 after market close on Tuesday, November 12, 2024. The Company’s management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time.

-Thirty-Two Percent of Life Science Marketing and Analytics Teams Report Not Knowing About or Not Using KPIs to Inform Shifts in Investment in Customer Engagement WALTHAM, Mass.--(BUSINESS WIRE)

--Trinity Life Sciences, the leader in strategy, insights and analytics for the life sciences industry, finds that thirty-two percent of life science marketing and analytics teams report not knowing about or not using key performance indicators (KPIs) to inform shifts in investment.

-Blood Collection Devices Market Report 2024 - Global Blood Collection Devices Market Forecast to Reach $17.2 Billion by 2030, Driven by Rising Chronic Diseases and Technological Progress - ResearchAndMarkets.com DUBLIN--(BUSINESS WIRE)

--The "Blood Collection Devices - A Global Market Overview" report has been added to ResearchAndMarkets.com's offering. The global Blood Collection Devices market is estimated at US$11.7 billion in 2024 and is expected to record a CAGR of 6.6% during the 2024-2030 analysis period and stand at a projected US$17.2 billion by 2030.